At a glance
| US product | Voxzogo |
|---|---|
| Target | Natriuretic peptide receptor B |
| Approved population | Children with achondroplasia and open epiphyses |
| Approval endpoint | Annualized growth velocity |
| Main precaution | Transient low blood pressure |
Overview
Achondroplasia is usually caused by an activating FGFR3 variant that restrains growth-plate development. Vosoritide acts downstream of this pathway through an engineered C-type natriuretic peptide analog. The US product Voxzogo is indicated for pediatric patients with achondroplasia and open epiphyses. Its accelerated approval was based on improved annualized growth velocity, and confirmatory evidence remains relevant to longer-term benefit. This distinction matters because faster growth over a trial period does not by itself settle every question about final adult height, function, complications, or quality of life. The treatment does not change the underlying genetic variant.
How it works
Vosoritide binds natriuretic peptide receptor B, a receptor with guanylyl cyclase activity, and increases intracellular cyclic GMP. This signaling counteracts part of the FGFR3–MAP kinase pathway that limits endochondral bone growth in achondroplasia. Activity therefore depends on functioning growth plates. Its vascular effects also explain the possibility of transient blood-pressure reductions, which are pharmacologically separate from its desired action in cartilage.
A condition-specific growth treatment
The indication requires achondroplasia and open growth plates. Age, growth trajectory, skeletal maturity, and the broader medical needs of achondroplasia remain relevant. A person with closed epiphyses cannot be assumed to gain additional bone length from stimulating this pathway. Vosoritide is not approved as a general height or bodybuilding intervention.
Supporting sources [1]
What the randomized trial showed
The phase 3 placebo-controlled trial demonstrated a greater increase in annualized growth velocity during the treatment year. The US indication uses accelerated approval based on that endpoint. Longer follow-up and confirmatory studies address durable clinical benefit, so results should be described precisely rather than equated with proof of every functional outcome.
Blood pressure and injection-related effects
Transient decreases in blood pressure can cause dizziness, fatigue, nausea, or faintness. The label emphasizes adequate hydration and food intake around administration. Injection-site reactions are common. Patients with significant cardiac or vascular disease were excluded from pivotal studies, which limits how confidently trial safety findings can be extended to those groups.
Supporting sources [1]
Does it cure achondroplasia?
No. Vosoritide modifies signaling that contributes to restricted longitudinal growth, but it does not replace the FGFR3 gene or remove the need for monitoring other achondroplasia complications. Growth measurements are meaningful outcomes, while neurologic, respiratory, orthopedic, and quality-of-life questions require their own evidence and follow-up.
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Modified 39-amino-acid C-type natriuretic peptide analog.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Voxzogo — US prescribing information ↗Regulatory source · Checked 2026-10-27
- Once-daily subcutaneous vosoritide in children with achondroplasia: a randomized phase 3 trial ↗Original research · Checked 2026-10-27